Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saline + autologous plasma is a therapeutic ophthalmic preparation used for the treatment of severe and recalcitrant dry eye disease. The formulation consists of plasma derived from the patient's own peripheral blood, which is typically diluted with sterile saline to concentrations such as 20% or 50%. This autologous biologic contains a concentrated array of essential components found in natural tears, including growth factors (such as EGF and TGF-β), fibronectin, vitamins, and immunoglobulins. These factors facilitate corneal epithelial wound healing, provide anti-inflammatory effects, and maintain the integrity of the ocular surface. By using the patient's own blood, the risk of immunological reactions or transmission of infectious diseases is minimized.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on saline + autologous plasma.